Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 8 of 8 entries
Sorted by: Best Match Show Resources per page
Human Epidermal Growth Factor Receptor 2-positive Mucinous Carcinoma with Signet Ring Cell Differentiation, Which Showed Complete Response after Neoadjuvant Chemotherapy.

Journal of breast cancer

Jang Y, Cho EY, Cho SY.
PMID: 31281734
J Breast Cancer. 2019 Mar 29;22(2):336-340. doi: 10.4048/jbc.2019.22.e17. eCollection 2019 Jun.

Mucinous carcinoma (MC) is a rare subtype of breast cancer, which is composed of tumor cells floating in the abundant extracellular mucin. This form of cancer is usually estrogen receptor/progesterone receptor positive and human epidermal growth factor receptor 2...

Cite
Jang Y, Cho EY, Cho SY. Human Epidermal Growth Factor Receptor 2-positive Mucinous Carcinoma with Signet Ring Cell Differentiation, Which Showed Complete Response after Neoadjuvant Chemotherapy. J Breast Cancer. 2019;22(2):336-340doi: 10.4048/jbc.2019.22.e17.
Jang, Y., Cho, E. Y., & Cho, S. Y. (2019). Human Epidermal Growth Factor Receptor 2-positive Mucinous Carcinoma with Signet Ring Cell Differentiation, Which Showed Complete Response after Neoadjuvant Chemotherapy. Journal of breast cancer, 22(2), 336-340. https://doi.org/10.4048/jbc.2019.22.e17
Jang, Yunjeong, et al. "Human Epidermal Growth Factor Receptor 2-positive Mucinous Carcinoma with Signet Ring Cell Differentiation, Which Showed Complete Response after Neoadjuvant Chemotherapy." Journal of breast cancer vol. 22,2 (2019): 336-340. doi: https://doi.org/10.4048/jbc.2019.22.e17
Jang Y, Cho EY, Cho SY. Human Epidermal Growth Factor Receptor 2-positive Mucinous Carcinoma with Signet Ring Cell Differentiation, Which Showed Complete Response after Neoadjuvant Chemotherapy. J Breast Cancer. 2019 Mar 29;22(2):336-340. doi: 10.4048/jbc.2019.22.e17. eCollection 2019 Jun. PMID: 31281734; PMCID: PMC6597410.
Copy Download .nbib Format: NLM
Accuracy of breast magnetic resonance imaging in evaluating the response to neoadjuvant chemotherapy: a study of 310 cases at a cancer center.

Radiologia brasileira

Negrão EMS, Bitencourt AGV, de Souza JA, Marques EF.
PMID: 31656346
Radiol Bras. 2019 Sep-Oct;52(5):299-304. doi: 10.1590/0100-3984.2018.0149.

OBJECTIVE: To evaluate the accuracy of magnetic resonance imaging (MRI) of the breasts in the identification of a pathological complete response in patients with breast cancer undergoing neoadjuvant chemotherapy (NAC).MATERIALS AND METHODS: This was a single-center, retrospective, observational study...

Cite
Negrão EMS, Bitencourt AGV, de Souza JA, et al. Accuracy of breast magnetic resonance imaging in evaluating the response to neoadjuvant chemotherapy: a study of 310 cases at a cancer center. Radiol Bras. 2019;52(5):299-304doi: 10.1590/0100-3984.2018.0149.
Negrão, E. M. S., Bitencourt, A. G. V., de Souza, J. A., & Marques, E. F. (2019). Accuracy of breast magnetic resonance imaging in evaluating the response to neoadjuvant chemotherapy: a study of 310 cases at a cancer center. Radiologia brasileira, 52(5), 299-304. https://doi.org/10.1590/0100-3984.2018.0149
Negrão, Erika Marina Solla, et al. "Accuracy of breast magnetic resonance imaging in evaluating the response to neoadjuvant chemotherapy: a study of 310 cases at a cancer center." Radiologia brasileira vol. 52,5 (2019): 299-304. doi: https://doi.org/10.1590/0100-3984.2018.0149
Negrão EMS, Bitencourt AGV, de Souza JA, Marques EF. Accuracy of breast magnetic resonance imaging in evaluating the response to neoadjuvant chemotherapy: a study of 310 cases at a cancer center. Radiol Bras. 2019 Sep-Oct;52(5):299-304. doi: 10.1590/0100-3984.2018.0149. PMID: 31656346; PMCID: PMC6808623.
Copy Download .nbib Format: NLM
Clinicopathologic characteristics of HER2-positive pure mucinous carcinoma of the breast.

Journal of pathology and translational medicine

Jang Y, Jung H, Kim HN, Seo Y, Alsharif E, Nam SJ, Kim SW, Lee JE, Park YH, Cho EY, Cho SY.
PMID: 31718120
J Pathol Transl Med. 2020 Jan;54(1):95-102. doi: 10.4132/jptm.2019.10.24. Epub 2019 Nov 13.

BACKGROUND: Pure mucinous carcinoma (PMC) is a rare type of breast cancer, estimated to represent 2% of invasive breast cancer. PMC is typically positive for estrogen receptors (ER) and progesterone receptors (PR) and negative for human epidermal growth factor...

Cite
Jang Y, Jung H, Kim HN, et al. Clinicopathologic characteristics of HER2-positive pure mucinous carcinoma of the breast. J Pathol Transl Med. 2019;54(1):95-102doi: 10.4132/jptm.2019.10.24.
Jang, Y., Jung, H., Kim, H. N., Seo, Y., Alsharif, E., Nam, S. J., Kim, S. W., Lee, J. E., Park, Y. H., Cho, E. Y., & Cho, S. Y. (2020). Clinicopathologic characteristics of HER2-positive pure mucinous carcinoma of the breast. Journal of pathology and translational medicine, 54(1), 95-102. https://doi.org/10.4132/jptm.2019.10.24
Jang, Yunjeong, et al. "Clinicopathologic characteristics of HER2-positive pure mucinous carcinoma of the breast." Journal of pathology and translational medicine vol. 54,1 (2020): 95-102. doi: https://doi.org/10.4132/jptm.2019.10.24
Jang Y, Jung H, Kim HN, Seo Y, Alsharif E, Nam SJ, Kim SW, Lee JE, Park YH, Cho EY, Cho SY. Clinicopathologic characteristics of HER2-positive pure mucinous carcinoma of the breast. J Pathol Transl Med. 2020 Jan;54(1):95-102. doi: 10.4132/jptm.2019.10.24. Epub 2019 Nov 13. PMID: 31718120; PMCID: PMC6986976.
Copy Download .nbib Format: NLM
Increased Expression of Neuregulin 1 and erbB2 Tyrosine Kinase in the Bladder of Rats With Cyclophosphamide-Induced Interstitial Cystitis.

International neurourology journal

Song KH, Youn CS, Lee CL, Yang SW, Chang YS, Jeong SW, Sul CK.
PMID: 26620897
Int Neurourol J. 2015 Sep;19(3):158-63. doi: 10.5213/inj.2015.19.3.158. Epub 2015 Sep 22.

PURPOSE: The aim of this study was to evaluate changes in expressions of neuregulin (NRG)1 and erbB2 tyrosine kinase (ErbB2) in bladders of rats with cyclophosphamide (CYP)-induced interstitial cystitis (IC).METHODS: Twenty-four Sprague-Dawley rats were divided into the IC group...

Cite
Song KH, Youn CS, Lee CL, et al. Increased Expression of Neuregulin 1 and erbB2 Tyrosine Kinase in the Bladder of Rats With Cyclophosphamide-Induced Interstitial Cystitis. Int Neurourol J. 2015;19(3):158-63doi: 10.5213/inj.2015.19.3.158.
Song, K. H., Youn, C. S., Lee, C. L., Yang, S. W., Chang, Y. S., Jeong, S. W., & Sul, C. K. (2015). Increased Expression of Neuregulin 1 and erbB2 Tyrosine Kinase in the Bladder of Rats With Cyclophosphamide-Induced Interstitial Cystitis. International neurourology journal, 19(3), 158-63. https://doi.org/10.5213/inj.2015.19.3.158
Song, Ki Hak, et al. "Increased Expression of Neuregulin 1 and erbB2 Tyrosine Kinase in the Bladder of Rats With Cyclophosphamide-Induced Interstitial Cystitis." International neurourology journal vol. 19,3 (2015): 158-63. doi: https://doi.org/10.5213/inj.2015.19.3.158
Song KH, Youn CS, Lee CL, Yang SW, Chang YS, Jeong SW, Sul CK. Increased Expression of Neuregulin 1 and erbB2 Tyrosine Kinase in the Bladder of Rats With Cyclophosphamide-Induced Interstitial Cystitis. Int Neurourol J. 2015 Sep;19(3):158-63. doi: 10.5213/inj.2015.19.3.158. Epub 2015 Sep 22. PMID: 26620897; PMCID: PMC4582087.
Copy Download .nbib Format: NLM
Measuring Tumor Extent Based on Subtypes Using Magnetic Resonance Imaging: Radiologic-Pathologic Discordance and High Positive Margin Rates in Breast Cancer.

Journal of breast cancer

Bae SJ, Ahn SG, Yoon CI, Yang BS, Lee HW, Son EJ, Jeong J.
PMID: 31598344
J Breast Cancer. 2019 Aug 21;22(3):453-463. doi: 10.4048/jbc.2019.22.e36. eCollection 2019 Sep.

PURPOSE: We evaluated the clinical value of breast magnetic resonance imaging (MRI) in patients who underwent breast-conserving surgery (BCS). The degree of correlation between pathology size and MRI or ultrasonography (US) size was compared based on breast cancer subtypes....

Cite
Bae SJ, Ahn SG, Yoon CI, et al. Measuring Tumor Extent Based on Subtypes Using Magnetic Resonance Imaging: Radiologic-Pathologic Discordance and High Positive Margin Rates in Breast Cancer. J Breast Cancer. 2019;22(3):453-463doi: 10.4048/jbc.2019.22.e36.
Bae, S. J., Ahn, S. G., Yoon, C. I., Yang, B. S., Lee, H. W., Son, E. J., & Jeong, J. (2019). Measuring Tumor Extent Based on Subtypes Using Magnetic Resonance Imaging: Radiologic-Pathologic Discordance and High Positive Margin Rates in Breast Cancer. Journal of breast cancer, 22(3), 453-463. https://doi.org/10.4048/jbc.2019.22.e36
Bae, Soong June, et al. "Measuring Tumor Extent Based on Subtypes Using Magnetic Resonance Imaging: Radiologic-Pathologic Discordance and High Positive Margin Rates in Breast Cancer." Journal of breast cancer vol. 22,3 (2019): 453-463. doi: https://doi.org/10.4048/jbc.2019.22.e36
Bae SJ, Ahn SG, Yoon CI, Yang BS, Lee HW, Son EJ, Jeong J. Measuring Tumor Extent Based on Subtypes Using Magnetic Resonance Imaging: Radiologic-Pathologic Discordance and High Positive Margin Rates in Breast Cancer. J Breast Cancer. 2019 Aug 21;22(3):453-463. doi: 10.4048/jbc.2019.22.e36. eCollection 2019 Sep. PMID: 31598344; PMCID: PMC6769395.
Copy Download .nbib Format: NLM
Relative Survival Benefit by Hormonal Receptor Status of Adding Trastuzumab to Neoadjuvant Chemotherapy in Breast Cancer Patients.

Journal of breast cancer

Schneider J, Lee HJ, Nam SJ, Lee SJ, Jung JH, Jung SH, Lim ST, Jeon YW, Gwak H.
PMID: 32595988
J Breast Cancer. 2020 May 12;23(3):259-267. doi: 10.4048/jbc.2020.23.e34. eCollection 2020 Jun.

PURPOSE: Neoadjuvant chemotherapy (NAC) involving trastuzumab markedly increases pathologic complete response (pCR) rates in patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer. Despite increasing pCR rates, long-term survival gains are controversial owing to distinctive biologic behavior...

Cite
Schneider J, Lee HJ, Nam SJ, et al. Relative Survival Benefit by Hormonal Receptor Status of Adding Trastuzumab to Neoadjuvant Chemotherapy in Breast Cancer Patients. J Breast Cancer. 2020;23(3):259-267doi: 10.4048/jbc.2020.23.e34.
Schneider, J., Lee, H. J., Nam, S. J., Lee, S. J., Jung, J. H., Jung, S. H., Lim, S. T., Jeon, Y. W., & Gwak, H. (2020). Relative Survival Benefit by Hormonal Receptor Status of Adding Trastuzumab to Neoadjuvant Chemotherapy in Breast Cancer Patients. Journal of breast cancer, 23(3), 259-267. https://doi.org/10.4048/jbc.2020.23.e34
Schneider, Jean, et al. "Relative Survival Benefit by Hormonal Receptor Status of Adding Trastuzumab to Neoadjuvant Chemotherapy in Breast Cancer Patients." Journal of breast cancer vol. 23,3 (2020): 259-267. doi: https://doi.org/10.4048/jbc.2020.23.e34
Schneider J, Lee HJ, Nam SJ, Lee SJ, Jung JH, Jung SH, Lim ST, Jeon YW, Gwak H. Relative Survival Benefit by Hormonal Receptor Status of Adding Trastuzumab to Neoadjuvant Chemotherapy in Breast Cancer Patients. J Breast Cancer. 2020 May 12;23(3):259-267. doi: 10.4048/jbc.2020.23.e34. eCollection 2020 Jun. PMID: 32595988; PMCID: PMC7311364.
Copy Download .nbib Format: NLM
Epidemiologic Study of Human Epidermal Growth Factor Receptor 2 Expression in Advanced/Metastatic Gastric Cancer: an Assessment of Human Epidermal Growth Factor Receptor 2 Status in Tumor Tissue Samples of Gastric and Gastro-Esophageal Junction Cancer.

Journal of gastric cancer

Seo KW, Jeon T, Kim S, Kim SS, Kim K, Suh BJ, Hwang S, Choi S, Ryu S, Min JS, Lee YJ, Jee YS, Chae H, Yang DH, Lee SH.
PMID: 28337363
J Gastric Cancer. 2017 Mar;17(1):52-62. doi: 10.5230/jgc.2017.17.e6. Epub 2017 Mar 17.

PURPOSE: The Trastuzumab for gastric cancer (GC) trial identified human epidermal growth factor receptor 2 (HER2) as a predictor of successful treatment with trastuzumab (HER2 receptor targeting agent) among patients with advanced/metastatic GC. To date, the prevalence of HER2...

Cite
Seo KW, Jeon T, Kim S, et al. Epidemiologic Study of Human Epidermal Growth Factor Receptor 2 Expression in Advanced/Metastatic Gastric Cancer: an Assessment of Human Epidermal Growth Factor Receptor 2 Status in Tumor Tissue Samples of Gastric and Gastro-Esophageal Junction Cancer. J Gastric Cancer. 2017;17(1):52-62doi: 10.5230/jgc.2017.17.e6.
Seo, K. W., Jeon, T., Kim, S., Kim, S. S., Kim, K., Suh, B. J., Hwang, S., Choi, S., Ryu, S., Min, J. S., Lee, Y. J., Jee, Y. S., Chae, H., Yang, D. H., & Lee, S. H. (2017). Epidemiologic Study of Human Epidermal Growth Factor Receptor 2 Expression in Advanced/Metastatic Gastric Cancer: an Assessment of Human Epidermal Growth Factor Receptor 2 Status in Tumor Tissue Samples of Gastric and Gastro-Esophageal Junction Cancer. Journal of gastric cancer, 17(1), 52-62. https://doi.org/10.5230/jgc.2017.17.e6
Seo, Kyung Won, et al. "Epidemiologic Study of Human Epidermal Growth Factor Receptor 2 Expression in Advanced/Metastatic Gastric Cancer: an Assessment of Human Epidermal Growth Factor Receptor 2 Status in Tumor Tissue Samples of Gastric and Gastro-Esophageal Junction Cancer." Journal of gastric cancer vol. 17,1 (2017): 52-62. doi: https://doi.org/10.5230/jgc.2017.17.e6
Seo KW, Jeon T, Kim S, Kim SS, Kim K, Suh BJ, Hwang S, Choi S, Ryu S, Min JS, Lee YJ, Jee YS, Chae H, Yang DH, Lee SH. Epidemiologic Study of Human Epidermal Growth Factor Receptor 2 Expression in Advanced/Metastatic Gastric Cancer: an Assessment of Human Epidermal Growth Factor Receptor 2 Status in Tumor Tissue Samples of Gastric and Gastro-Esophageal Junction Cancer. J Gastric Cancer. 2017 Mar;17(1):52-62. doi: 10.5230/jgc.2017.17.e6. Epub 2017 Mar 17. PMID: 28337363; PMCID: PMC5362834.
Copy Download .nbib Format: NLM
Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab.

Journal of breast cancer

Ha JY, Kim JE, Lee HJ, Jeong JH, Ahn JH, Jung KH, Gong G, Chae EY, Kim HH, Chung IY, Ko BS, Kim SB.
PMID: 34352937
J Breast Cancer. 2021 Aug;24(4):359-366. doi: 10.4048/jbc.2021.24.e36. Epub 2021 Jul 09.

PURPOSE: The tumor-infiltrating lymphocytes (TILs) expression in breast cancer is a positive prognostic marker for certain breast cancer subtypes. We evaluated the efficacy of dual anti-human epidermal growth factor receptor 2 (HER2) blockade in HER2-positive breast cancer and hypothesized...

Cite
Ha JY, Kim JE, Lee HJ, et al. Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab. J Breast Cancer. 2021;24(4):359-366doi: 10.4048/jbc.2021.24.e36.
Ha, J. Y., Kim, J. E., Lee, H. J., Jeong, J. H., Ahn, J. H., Jung, K. H., Gong, G., Chae, E. Y., Kim, H. H., Chung, I. Y., Ko, B. S., & Kim, S. B. (2021). Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab. Journal of breast cancer, 24(4), 359-366. https://doi.org/10.4048/jbc.2021.24.e36
Ha, Joo Young, et al. "Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab." Journal of breast cancer vol. 24,4 (2021): 359-366. doi: https://doi.org/10.4048/jbc.2021.24.e36
Ha JY, Kim JE, Lee HJ, Jeong JH, Ahn JH, Jung KH, Gong G, Chae EY, Kim HH, Chung IY, Ko BS, Kim SB. Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab. J Breast Cancer. 2021 Aug;24(4):359-366. doi: 10.4048/jbc.2021.24.e36. Epub 2021 Jul 09. PMID: 34352937; PMCID: PMC8410619.
Copy Download .nbib Format: NLM
Showing 1 to 8 of 8 entries